Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALPNNASDAQ:KZRNASDAQ:SCYXNASDAQ:SNSSNASDAQ:TORC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shs2 shsKZRKezar Life Sciences$4.56+1.6%$4.30$3.62▼$9.18$33.46M0.652,227 shs22,529 shsSCYXSCYNEXIS$0.73+1.5%$0.85$0.66▼$2.29$28.54M1.57161,508 shs70,952 shsSNSSSunesis Pharmaceuticals$3.53$1.12▼$11.30$96.26M2.274.33 million shs1.20 million shsTORCresTORbio$0.61-1.1%$12.16$0.86▼$10.50$22.13M2.431.15 million shs545,982 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%KZRKezar Life Sciences0.00%+2.70%+4.11%+10.68%-21.26%SCYXSCYNEXIS0.00%+5.74%-17.47%-12.98%-62.32%SNSSSunesis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%TORCresTORbio0.00%-2.97%-23.26%-9.54%-44.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune SciencesN/AN/AN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences4.1966 of 5 stars3.23.00.04.60.73.30.6SCYXSCYNEXIS0.2634 of 5 stars0.03.00.00.00.00.80.6SNSSSunesis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences 0.00N/AN/AN/AKZRKezar Life Sciences 2.33Hold$39.50766.23% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ASNSSSunesis Pharmaceuticals 0.00N/AN/AN/ATORCresTORbio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$56.52M78.85N/AN/A$4.85 per share13.40KZRKezar Life SciencesN/AN/AN/AN/A$16.02 per shareN/ASCYXSCYNEXIS$3.75M7.61N/AN/A$1.45 per share0.50SNSSSunesis Pharmaceuticals$2.07M0.00N/AN/A$1.42 per share0.00TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/AKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.56N/A14.62N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)SNSSSunesis Pharmaceuticals-$23.33M-$2.70N/AN/AN/AN/A-179.05%-72.27%N/ATORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/ALatest ALPN, SCYX, TORC, SNSS, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ASNSSSunesis PharmaceuticalsN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A9.569.56KZRKezar Life Sciences0.047.097.09SCYXSCYNEXISN/A5.835.83SNSSSunesis PharmaceuticalsN/A7.747.74TORCresTORbioN/A20.6920.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%KZRKezar Life Sciences67.90%SCYXSCYNEXIS54.37%SNSSSunesis Pharmaceuticals28.41%TORCresTORbio46.19%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%KZRKezar Life Sciences10.40%SCYXSCYNEXIS4.86%SNSSSunesis Pharmaceuticals4.22%TORCresTORbio11.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences14268.60 million39.58 millionOptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableSCYXSCYNEXIS6039.02 million37.12 millionOptionableSNSSSunesis Pharmaceuticals2418.09 millionN/AOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableALPN, SCYX, TORC, SNSS, and KZR HeadlinesRecent News About These CompaniesJohn FlynnApril 24, 2024 | fleetowner.comFAdicet Bio Inc (ACET)January 30, 2024 | investing.comTargeting the biology of aging with mTOR inhibitors - Nature.comMay 4, 2023 | news.google.comNPARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLiveMarch 17, 2023 | news.google.comNMichelle Chaka Joins Torc as Senior Vice President, Safety and RegulatoryFebruary 24, 2023 | finance.yahoo.comTorc names regulatory, safety SVPFebruary 24, 2023 | virginiabusiness.comVGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRFebruary 8, 2023 | news.google.comNPhenotypic Presentations and the Management of Moderate to ... - HealioJanuary 31, 2023 | news.google.comNAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comJanuary 23, 2023 | news.google.comNAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswireJanuary 23, 2023 | news.google.comNTinOne Resources Inc. (TORC.V)January 10, 2023 | finance.yahoo.comresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities NewsDecember 16, 2022 | news.google.comNresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities NewsDecember 12, 2022 | news.google.comNBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.TechnologyNovember 3, 2022 | news.google.comNTORC Investments, LLCOctober 6, 2022 | gwinnettdailypost.comGCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - ForbesSeptember 19, 2022 | forbes.comFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business JournalsSeptember 12, 2022 | bizjournals.comCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRSeptember 6, 2022 | openpr.comFor preventing aging, some decades old drugs? - BioWorld OnlineJuly 18, 2022 | bioworld.comBForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comJuly 8, 2022 | streetinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALPN, SCYX, TORC, SNSS, and KZR Company DescriptionsAlpine Immune Sciences NASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Kezar Life Sciences NASDAQ:KZR$4.56 +0.07 (+1.56%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.SCYNEXIS NASDAQ:SCYX$0.73 +0.01 (+1.51%) Closing price 07/3/2025 02:22 PM EasternExtended Trading$0.72 -0.02 (-2.19%) As of 07/3/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Sunesis Pharmaceuticals NASDAQ:SNSSSunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.resTORbio NASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
